Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
It is very uncertain whether induced hypertension changes death from all causes (primary outcome) compared with placebo or no intervention (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether induced hypertension changes death or dependency (primary outcome) compared with placebo or no intervention (very low certainty).
It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).
It is very uncertain whether induced hypertension changes delayed cerebral ischaemia compared with placebo or no intervention (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether lowered blood pressure changes death from all causes (primary outcome) compared with placebo (very low certainty).
The review found no eligible studies for this question.
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (any cause) compared with control (placebo or standard care) (moderate certainty).
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower cardiovascular and cerebrovascular morbidity compared with control (placebo or standard care) (moderate certainty).
Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).